Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2017

Open Access 01-12-2017 | Research article

B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review

Authors: Nathaniel M. Hawkins, Amit Khosla, Sean A. Virani, John J. V. McMurray, J Mark FitzGerald

Published in: BMC Pulmonary Medicine | Issue 1/2017

Login to get access

Abstract

Background

Patients with chronic obstructive pulmonary disease (COPD) have increased cardiovascular risk. Natriuretic peptides (NP) in other populations are useful in identifying cardiovascular disease, stratifying risk, and guiding therapy.

Methods

We performed a systematic literature review to examine NP in COPD, utilising Medline, EMBASE, and the Cochrane Library.

Results

Fifty one studies were identified. NP levels were lower in stable compared to exacerbation of COPD, and significantly increased with concomitant left ventricular systolic dysfunction or cor pulmonale. Elevation occurred in 16 to 60% of exacerbations and persisted in approximately one half of patients at discharge. Cardiovascular comorbidities were associated with increased levels. Levels consistently correlated with pulmonary artery pressure and left ventricular ejection fraction, but not pulmonary function or oxygen saturation. NP demonstrated high negative predictive values (0.80 to 0.98) to exclude left ventricular dysfunction in both stable and exacerbation of COPD, but relatively low positive predictive values. NP elevation predicted early adverse outcomes, but the association with long term mortality was inconsistent.

Conclusion

NP reflect diverse aspects of the cardiopulmonary continuum which limits utility when applied in isolation. Strategies integrating NP with additional variables, biomarkers and imaging require further investigation.
Appendix
Available only for authorised users
Literature
1.
Keistinen T, Tuuponen T, Kivela SL. Survival experience of the population needing hospital treatment for asthma or COPD at age 50–54 years. Respir Med. 1998;92:568–72.CrossRefPubMed
2.
Vilkman S, Keistinen T, Tuuponen T, Kivela SL. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration. 1997;64:281–4.CrossRefPubMed
3.
McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax. 2007;62:411–5.CrossRefPubMedPubMedCentral
4.
Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130–9.CrossRefPubMedPubMedCentral
5.
6.
7.
Sin DD, Hollander Z, DeMarco ML, McManus BM, Ng RT. Biomarker development for chronic obstructive pulmonary disease. From discovery to clinical implementation. Am J Respir Crit Care Med. 2015;192:1162–70.CrossRefPubMed
8.
Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:728–35.CrossRefPubMed
9.
Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655–63.CrossRefPubMed
10.
Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66–74.CrossRefPubMed
11.
Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. J Clin Epidemiol. 2012;65:163–78.CrossRefPubMed
12.
Viswanathan M, Berkman ND, Dryden DM, Hartling L. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI item bank. Rockville: Agency for Healthcare Research and Quality Methods Research Report; 2013.
13.
14.
15.
Bland M. Estimating mean and standard deviation from the sample size, three quartiles, minimum, and maximum. Int J Stat Med Res. 2015;4:57.CrossRef
16.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.CrossRefPubMedPubMedCentral
17.
Anderson WJ, Lipworth BJ, Rekhraj S, Struthers AD, George J. Left ventricular hypertrophy in COPD without hypoxemia: the elephant in the room? Chest. 2013;143:91–7.CrossRefPubMed
18.
Gemici G, Erdim R, Celiker A, Tokay S, Ones T, Inanir S, Oktay A. B-type natriuretic peptide levels in patients with COPD and normal right ventricular function. Adv Ther. 2008;25:674–80.CrossRefPubMed
19.
Sahin Ozdemirel T, Sarin Ulasli S, Yetis B, Karacaglar E, Bayraktar N, Ulubay G. Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD: an observational study. Anadolu Kardiyol Derg. 2014;14:370–7.CrossRef
20.
Wang HY, Xu QF, Xiao Y, Zhang J, Sperry A. Cardiac response and N-terminal-pro-brain natriuretic peptide kinetics during exercise in patients with COPD. Respir Care. 2011;56:796–9.CrossRefPubMed
21.
Boschetto P, Campo I, Stendardo M, et al. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Investig. 2013;43:562–9.CrossRef
22.
Wang R, Cao Z, Li Y, Yu K. Utility of N-terminal pro B-type natriuretic peptide and mean platelet volume in differentiating congestive heart failure from chronic obstructive pulmonary disease. Int J Cardiol. 2013;170:e28–e9.CrossRefPubMed
23.
Beghe B, Verduri A, Bottazzi B, et al. Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: an observational study. PLoS One. 2013;8:e80166.CrossRefPubMedPubMedCentral
24.
Rutten FH, Cramer MJ, Zuithoff NP, Lammers JW, Verweij W, Grobbee DE, Hoes AW. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail. 2007;9:651–9.CrossRefPubMed
25.
Gale CP, White JES, Hunter A, et al. Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical and echocardiographic assessment. J Cardiovasc Med. 2011;12:613–8.CrossRef
26.
Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012;39:51–8.CrossRefPubMed
27.
Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med. 1999;93:507–14.CrossRefPubMed
28.
Bozkanat E, Tozkoparan E, Baysan O, Deniz O, Ciftci F, Yokusoglu M. The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease. J Int Med Res. 2005;33:537–44.CrossRefPubMed
29.
Anar C, Yildirim E, Buyuksirin M, Halilcolar H. Diagnostic value of N-terminal pro-B-type natriuretic peptide levels in patients with chronic obstructive pulmonary diseases. Anatolian J Clin Investig. 2012;6:86–91.
30.
Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med. 2008;177:743–51.CrossRefPubMed
31.
Kanat F, Vatansev H, Teke T. Diuretics, plasma brain natriuretic peptide and chronic obstructive pulmonary disease. Neth J Med. 2007;65:296–300.PubMed
32.
Wang QP, Cao XZ, Wang XD, et al. Utility of NT-proBNP for identifying LV failure in patients with acute exacerbation of chronic bronchitis. PLoS ONE [Electron Resour]. 2013;8:e52553.CrossRef
33.
Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest. 2008;133:1088–94.CrossRefPubMed
34.
Marcun R, Sustic A, Brguljan PM, et al. Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol. 2012;161:156–9.CrossRefPubMed
35.
Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med. 2009;48:503–12.CrossRefPubMed
36.
Nishimura K, Nishimura T, Onishi K, Oga T, Hasegawa Y, Jones PW. Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. Int J COPD. 2014;9:155–62.CrossRef
37.
Lee MH, Chang CL, Davies AR, Davis M, Hancox RJ. Cardiac dysfunction and N-terminal pro-B-type natriuretic peptide in exacerbations of chronic obstructive pulmonary disease. Intern Med J. 2013;43:595–8.CrossRefPubMed
38.
Patel ARC, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188:1091–9.CrossRefPubMedPubMedCentral
39.
El Mallawany H, Mahmoud MI, Morsi TS, EL-Shiekh RM. Role of N-terminal pro B-type natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc. 2014;63:57–65.CrossRef
40.
Patel ARC, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest. 2012;141:851–7.CrossRefPubMed
41.
Akpinar EE, Hosgun D, Akpinar S, Atac GK, Doganay B, Gulhan M. Incidence of pulmonary embolism during COPD exacerbation. J Bras Pneumol. 2014;40:38–45.CrossRefPubMedPubMedCentral
42.
Andersen CU, Mellemkjaer S, Nielsen-Kudsk JE, Sonderskov LD, Laursen BE, Simonsen U, Hilberg O. Echocardiographic screening for pulmonary hypertension in stable COPD out-patients and NT-proBNP as a rule-out test. COPD: J Chron Obstruct Pulmon Dis. 2012;9:505–12.CrossRef
43.
Ouanes I, Jalloul F, Ayed S, et al. N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction. Respirology. 2012;17:660–6.CrossRefPubMed
44.
Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, Hancox RJ. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66:764–8.CrossRefPubMed
45.
Hoiseth AD, Omland T, Hagve TA, Brekke PH, Soyseth V. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study. Respir Res. 2012;13:97.CrossRefPubMedPubMedCentral
46.
Abroug F, Ouanes-Besbes L, Nciri N, et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med. 2006;174:990–6.CrossRefPubMed
47.
Gariani K, Delabays A, Perneger TV, Agoritsas T. Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Swiss Med Wkly. 2011;141:w13298.PubMed
48.
Waschki B, Kirsten A, Holz O, Muller KC, Meyer T, Watz H, Magnussen H. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331–42.CrossRefPubMed
49.
van Gestel YR, Goei D, Hoeks SE, et al. Predictive value of NT-proBNP in vascular surgery patients with COPD and normal left ventricular systolic function. COPD. 2010;7:70–5.CrossRefPubMed
50.
Zeng LH, Hu YX, Liu L, Zhang M, Cui H. Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging. 2013;8:1157–65.PubMedPubMedCentral
51.
Lee JH, Oh SY, Hwang I, Kim O, Kim HK, Kim EK, Lee JH. The prognostic role of B-type natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease. [Korean]. Tuberc Respir Dis. 2004;56:600–10.CrossRef
52.
Medina AM, Marteles MS, Saiz EB, Martinez SS, Laiglesia FR, Rodriguez JAN, Perez-Calvo JI. Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases. Eur. 2011;22:167–71.
53.
Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest. 2004;126:1330–6.CrossRefPubMed
54.
O’Donoghue M, Chen A, Baggish AL, Anwaruddin S, Krauser DG, Tung R, Januzzi JL. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP investigation of dyspnea in the emergency department (PRIDE) study. J Card Fail. 2005;11:S9–14.CrossRefPubMed
55.
Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the breathing Not properly multinational study. J Am Coll Cardiol. 2003;41:2010–7.CrossRefPubMed
56.
Blyth KG, Groenning BA, Mark PB, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J. 2007;29:737–44.CrossRefPubMed
57.
Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C, Konstantinides S. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation. 2005;112:1573–9.CrossRefPubMed
58.
Bazzino O, Fuselli JJ, Botto F, Perez DA, Bahit C, Dadone J. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2004;25:859–66.CrossRefPubMed
59.
Lindahl B, Lindback J, Jernberg T, Johnston N, Stridsberg M, Venge P, Wallentin L. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a fragmin and fast revascularisation during in stability in coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol. 2005;45:533–41.CrossRefPubMed
60.
Gerber IL, Stewart RA, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation. 2003;107:1884–90.CrossRefPubMed
61.
Morello A, Lloyd-Jones DM, Chae CU, et al. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP investigation of dyspnea in the emergency department (PRIDE) study. Am Heart J. 2007;153:90–7.CrossRefPubMed
62.
Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med. 2007;167:400–7.CrossRefPubMed
63.
Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–12.CrossRefPubMed
64.
Zvezdin B, Milutinov S, Kojicic M, Hadnadjev M, Hromis S, Markovic M, Gajic O. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009;136:376–80.CrossRefPubMed
65.
Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9:e113048.CrossRefPubMedPubMedCentral
66.
Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47:2554–60.CrossRefPubMed
67.
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7.CrossRefPubMed
68.
Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP study. Eur Heart J. 2006;27:330–7.CrossRefPubMed
69.
Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910.CrossRefPubMedPubMedCentral
70.
Cleland JG, McMurray JJ, Kjekshus J, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (controlled rosuvastatin multinational trial in heart failure). J Am Coll Cardiol. 2009;54:1850–9.CrossRefPubMed
71.
Fujii T, Otsuka T, Tanaka S, et al. Plasma endothelin-1 level in chronic obstructive pulmonary disease: relationship with natriuretic peptide. Respiration. 1999;66:212–9.CrossRefPubMed
72.
Cabanes L, Richaud-Thiriez B, Fulla Y, Heloire F, Vuillemard C, Weber S, Dusser D. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest. 2001;120:2047–50.CrossRefPubMed
73.
Hemlin M, Ljungman S, Carlson J, Maljukanovic S, Mobini R, Bech-Hanssen O, Skoogh BE. The effects of hypoxia and hypercapnia on renal and heart function, haemodynamics and plasma hormone levels in stable COPD patients. Clin Respir J. 2007;1:80–90.CrossRefPubMed
74.
Papaioannou AI, Mazioti A, Kiropoulos T, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med. 2010;104:275–82.CrossRefPubMed
75.
Kim MA, Kim DK, Lee CH, Chung HS. The correlation of brain natriuretic peptide (BNP), pulmonary arterial pressure, and St. George respiratory questionnaire (SGRQ) and their changes with a trial of an angiotensin converting enzyme inhibitor. [Korean]. Tuberc Respir Dis. 2010;68:273–9.CrossRef
76.
Murphy CA, Blyth KG, Chaudhuri R, et al. Assessment of the presence of occult myocardial infarction in chronic obstructive pulmonary disease using contrast-enhanced cardiac magnetic resonance imaging. Respiration. 2009;78:263–9.CrossRefPubMed
77.
Rubinsztajn R, Nasilowski J, Przybylowski T, Karwat K, Chazan R. Usefulness of NT-proBNP serum level in the diagnosis of dyspnea in COPD patients. Pneumonol Alergol Pol. 2013;81:24–9.PubMed
78.
Lopez-Sanchez M, Munoz-Esquerre M, Huertas D, et al. High prevalence of left ventricle diastolic dysfunction in severe COPD associated with a Low exercise capacity: a cross-sectional study. PLoS ONE. 2013;8.
79.
Agoston-Coldea L, Lupu S, Hicea S, Paradis A, Mocan T. Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction. Biomark Med. 2014;8:95–106.CrossRefPubMed
80.
Xie X, Wang X, Zhang Y, Han D, Li S, Li M. [Correlation between serum marker variations and pulmonary hypertension secondary to chronic obstructive pulmonary disease]. Nan fang yi ke da xue xue bao = J of South Med Univ. 2013;33:1458–62.
81.
Escande W, Duva Pentiah A, Coisne A, et al. Left ventricular myocardial performance index predicts poor outcome during COPD exacerbation. Int J Cardiol. 2014;173:575–8.CrossRefPubMed
82.
Martins CS, Rodrigues MJ, Miranda VP, Nunes JP. Prognostic value of cardiac troponin I in patients with COPD acute exacerbation. Neth J Med. 2009;67:341–9.PubMed
83.
Sanchez-Marteles M, Cecilio-Irazola A, Vano-Sanchis D, Nuviala-Mateo R, Serrano-Martinez S, Perez-Calvo JI. NT-proBNP in chronic obstructive pulmonary disease patients. [spanish]. An Sist Sanit Navar. 2009;32:235–41.CrossRefPubMed
84.
Chi SY, Kim EY, Ban HJ, et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung. 2012;190:271–6.CrossRefPubMedPubMedCentral
85.
Hwang YI, Geun MP, Sung YK, et al. Correlation between NT-proBNP and pulmonary arterial pressure in COPD patients. [Korean]. Tuberc Respir Dis. 2007;63:346–52.CrossRef
86.
Mansour AE, Abdelsamad AA, El Arman MM. Prognostic value of plasma brain natriuretic peptide in patients with stable chronic obstructive pulmonary disease. Egyptian J Chest Dis Tuberc. 2012;61:297–300.CrossRef
87.
Jelic S, Le Jemtel TH. Diagnostic usefulness of B-type natriuretic peptide and functional consequences of muscle alterations in COPD and chronic heart failure. Chest. 2006;130:1220–30.CrossRefPubMed
88.
Sanchez-Marteles M, Molina Medina A, Bermejo Saiz E, Ruiz Laiglesia F, Nieto Rodriguez JA, Perez-Calvo JI. Prognostic value of NT-proBNP in chronic pulmonary disease exacerbation. Med Clin. 2010;135:441–6.CrossRef
Metadata
Title
B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review
Authors
Nathaniel M. Hawkins
Amit Khosla
Sean A. Virani
John J. V. McMurray
J Mark FitzGerald
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2017
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-016-0345-7

Other articles of this Issue 1/2017

BMC Pulmonary Medicine 1/2017 Go to the issue

Case report

Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia

Research article

Delay in diagnosis of pulmonary tuberculosis in low-and middle-income settings: systematic review and meta-analysis

Research article

Serological and morphological prognostic factors in patients with interstitial pneumonia with autoimmune features

Research article

Reference Equations for the Six-Minute Walk Distance in the Healthy Chinese Han Population, Aged 18–30 Years

Research article

Long-term prognosis of chronic cough: a prospective, observational cohort study

Study protocol

The efficacy of initial ventilation strategy for adult immunocompromised patients with severe acute hypoxemic respiratory failure: study protocol for a multicentre randomized controlled trial (VENIM)

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits